Essentials
• New VWF activity assays are increasingly used but information on their comparability is limited.
• This is an ISTH SSC-organized study (expert labs, 5 countries) to compare all available assays.
• VWF activity by six assays correlated well with each other.
• The new assays show improved characteristics -minor differences are noted.
Summary. Background: Several new assays have become available to measure von Willebrand factor (VWF) activity. The new assays appear to have improved performance characteristics compared with the old reference standard, ristocetin cofactor activity (VWF:RCo), but information is limited about how they compare with VWF:RCo and each other. Methods: The von Willebrand factor Subcommittee of the International Society for Thrombosis and Haemostasis (ISTH) Scientific and Standardization Committee (SSC) designed a collaborative study involving expert laboratories from several countries to compare available tests with each other and with VWF:RCo. Eight laboratories from five countries were provided with blinded samples from normal healthy individuals and well-characterized clinical cases. Laboratories measured VWF activity using all tests available to them; data from six laboratories, not affected by thawing during transportation, are included in this study. Results: All tests correlated well with VWF:RCo activity (r-values ranged from 0.963 to 0.989). Slightly steeper regression lines for VWF:Ab and VWF:GPIbM were clinically insignificant.
The new assays showed improved performance characteristics. Of the commercially available assays, the VWF: GPIbR using the AcuStar system was the most sensitive and could reliably detect VWF activity below 1 IU dL À1 .
The lower limit of the measuring interval for the VWF: GPIbM and the VWF:GPIbR assays was in the 3-4 and 3-6 IU dL À1 range, respectively. Inter-laboratory varia-
Introduction

Measuring von Willebrand factor (VWF) activity is central to the correct diagnosis and classification of von
Willebrand disease (VWD), the most common bleeding disorder in man [1] . Ristocetin cofactor activity (VWF: RCo), the former reference standard for measuring VWF to platelet GPIb binding relies on the ability of VWF in a patient's plasma to agglutinate platelets in the presence of ristocetin. The assay procedure suffers from numerous shortcomings, including poor precision and sensitivity, which has led to the development of several new assays with improved performance characteristics. Some of the issues related to VWF activity testing have recently been reviewed [2] [3] [4] [5] [6] . However, there is limited information about how these assays compare with VWF:RCo and with each other. Therefore, the von Willebrand factor Subcommittee of the International Society for Thrombosis and Haemostasis (ISTH) Scientific and Standardization Committee (SSC) undertook to design a collaborative study involving expert laboratories from several countries to compare all available tests with each other and with the VWF:RCo assay. This paper uses the nomenclature recently recommended by the VWF subcommittee of the ISTH SSC [7] .
Methods
An independent international multicenter study was organized by the ISTH SSC VWF Subcommittee (Comparison of Assays to Measure VWF Activity, COMPASS-VWF). Eight laboratories participated (Germany, three laboratories; Italy, two laboratories; Hungary, the UK and the USA, one laboratory each). Each of the participating centers was assigned a laboratory identification (Laboratory 1 through to Laboratory 8), and provided with 95 frozen and blinded, double-spun platelet-poor plasma samples (dispatched on dry ice). These consisted of 53 samples from normal healthy individuals, and 42 samples from VWD patients. The latter group comprised: 11 type 1, 21 type 2 and six type 3 patients, as well as four recombinant VWF proteins (diluted in a type 3 VWD patient's plasma). All subtypes were represented in the type 2 group: 10 2A, two 2B, three 2M and six 2N patients. Only samples from thoroughly characterized patients were included, and availability of the molecular defect resulting in the particular VWD type was required from all patients. The frozen samples sent to Laboratory 7 and Laboratory 8 were inadvertently thawed during transportation, and were excluded from this study; thus, data from only six centers are included in the current analysis. 
Data management
Results were submitted to the organizing center, sample blinding was decoded and results were entered into the database. 1 Outliers were removed for all analyses, as follows: for each plasma sample, measurements from all activity assays across all laboratories were pooled, and the outliers were identified by Grubbs' test with P < 0.01 for each plasma sample. In this way, a total of 14 measurements (0.7% of data points) were removed. Outliers are felt to be the result of errors (pipetting errors, transcription errors, etc.). As expected, the highest number of outlier measurements was from VWF:RCo; otherwise, no identifiable pattern in the distribution of the removed outliers was observed (i.e. no clustering of the errors with any assay or VWD type) (Table S1 ). 2 For all regression analyses, measurement readings under the lower limit of measuring interval (LLMI) were arbitrarily replaced by the half of the limit (LLMI/2).
3 In the sensitivity analysis, the lowest limits used in each laboratory were noted and compared with the LLMI shown on the official label by the distributing company. 4 In the coefficient of variation (CV) analysis, samples with more than one measurement < LLMI were removed, and samples reported for any particular assay as < LLMI measurement in one laboratory only were kept, and the < LLMI measurement was replaced by LLMI/2. For each VWF activity group and antigen measurement, results were averaged across laboratories for each plasma sample.
Analysis
The analysis was conducted in R package 'mcr' [9] and Passing & Bablok regression and Bland-Altman methods were used to compare assays. The data are presented graphically with estimates of intercept (I) and slope (S), together with their associated 95% confidence intervals (CIs) and correlation coefficient (r). Inter-laboratory percentage CV was calculated for each sample and each assay (three to five measurement points, as shown in Table 2 ). The mean of 95 such CV values is shown in Table 2 . Our sample size (n = 95) has 90% power to prove agreement at the significance level of 0.05, with no difference (l/r = 0), allowing for a standardized agreement limit (d/r) of 2.6, or 80% power to prove agreement with a standardized difference of 0.1 (l/r = 0.1), where r is the standard deviation (SD) of the measurements, l is the mean difference between methods and d is the limit of agreement [10] .
Results
Correlation of VWF activity as measured by different activity assays 1 All tests correlated well with the VWF:RCo activity (r-values ranged from 0.963 to 0.989; P < 0.001 for all comparisons) ( Fig. 1 ; P < 0.001). However, both the IL VWF:Ab and Siemens VWF:GPIbM assays gave slightly higher results, whereas the 'in-house' ELISA yielded slightly lower activity. These differences were statistically significant (the line of identity fell outside the 95% CI), but not clinically/biologically relevant ( Fig. 1 ). 2 Comparison by laboratory: to assess whether these small between-assay differences were a result of technical issues associated with a particular laboratory, we analyzed the sample results separately for each laboratory ( Fig. 2 ). This procedure detected some differences between laboratories, especially in the VWF:RCo comparison, but the slightly steeper slope for VWF:Ab and VWF:GPIbM remained consistent across all laboratories. As mentioned before, the small difference would not be expected to have an impact on clinical interpretation. 3 Normal and clinical samples: we analyzed normal and VWD samples separately (Fig. 3) . Figure 3 is a BlandAltman plot showing differences between the newer assays and VWF:RCo as a function of VWF activity value. Again, the slightly different slope is reflected in the difference that is consistent through the low and normal ranges for VWF:Ab and the VWF:GPIbM assay, but the magnitude of the difference is slightly larger with the normal VWF activity values. Figure 3 shows different VWD types. As expected, the majority of VWD samples are clustered around the baseline. Some of the 2N samples deviate more for VWF: GPIbR. However, this would not affect the diagnosis because the diagnosis of VDW 2N is based on FVIII levels and VWF:FVIII binding, not VWF activity. 4 The effect of different calibrators: to study the effect of different calibrators, two participating laboratories performed VWF:RCo and VWF:GPIbM using the SSC calibrator plasma in addition to the calibrator routinely used by the laboratory (Fig. 4) , which was Siemens Standard Human Plasma for both laboratories and specified by the company (Laboratories 1 and 4) participating in this part of the exercise. The values obtained with the different calibrators were close to identity, as seen in Fig. 4 .
Sensitivity Table 1 shows the LLMI (below which results were reported as < LLMI) used by each laboratory. The LLMI, as claimed in the manufacturer's labeling, is also shown. Based on internal validation [11] , several laboratories were able to use lower limits. The most sensitive assay was the 'in-house' ELISA, followed by the AcuStar VWF:GPIbR.
Precision
This study assessed inter-laboratory variation (multiple laboratories in different countries measuring the same samples at different times), as opposed to the typically reported intra-laboratory variation, which is calculated in a single laboratory under standardized conditions. Most of the new assays evaluated exhibited performance characteristics in excess of those shown by VWF:RCo ( Table 2) . As expected, variability in the low range (i.e. VWD samples) was greater than that seen with normal samples.
Discussion
The introduction of new assays to measure VWF activity is a most welcome development in the diagnosis of VWD, to simplify and allow for a more specific laboratory evaluation of VWF activity. However, the availability of different assays using different measuring principles has caused confusion among clinicians and laboratory physicians alike. We report the results of COMPASS-VWF study, an independent international comparison organized by the VWF Subcommittee of the ISTH SSC, which compared VWF activity assays performed in different expert laboratories. As expected, and also reported by others, all of the new assays (i.e. VWF:GPIbR by the HemosIL latex agglutination assay [12] [13] [14] and the HemosIL AcuStar assay [12, [15] [16] [17] [18] , the VWF:GPIbM Siemens assay [15, [19] [20] [21] [22] [23] [24] To test whether the detected difference is a result of a technical issue in some participating laboratories, we analyzed the samples separately in each laboratory (Fig. 2) and found that the small differences were consistent across all participating laboratories, pointing toward an intrinsic feature of the assays as a potential explanation for the difference. Similarly, the slight difference in the regression slope was present in both low (VWD) and normal ranges (Fig. 3) . It is noted that a similar small difference has been demonstrated by some [20, 30, 31] but not all [19] investigators for GPIbM. The reason for the discrepancy is not clear; however, the small differences would have no impact in clinical practice. On the other hand, in external quality assurance programs for VWF activity testing, such information is essential when different laboratories report VWF activity using different assays. It is also noted that some patient samples behaved differently in different assays. This appears to be a function of the specific assays. For example, the recombinant sample with the mutation p.P1467S shows lower activity with most assays dependent on ristocetin (known to be falsely low [32, 33] ) as compared with the VWF:GPIbM or VWF:Ab assays (Fig. 1) . For other samples, the precise mechanism for the discrepancy remains unclear. . Some expert laboratories are able to go lower using a special protocol [11] , but this is not available in most clinical laboratories. The most sensitive assay was the 'in-house' ELISA and the AcuStar assay measuring VWF:GPIbM and VWF:GPIbR, respectively, the latter using a chemiluminescent detection system. Both assays could reliably measure VWF activity below 1 IU dL À1 ( Table 1 ). The VWF:GPIbM and the VWF:GPIbR assays had LLMIs in the 3-4 IU dL À1 and 3-6 IU dL À1 range, respectively, whereas the VWF:Ab assay seems less sensitive (LLMI, 19 IU dL À1 ). Improved sensitivity is a most important development with the introduction of these new assays, because classifying moderate to severe VWD is only possible with the reliable measurement of VWF activity in the low range.
Our study assessed inter-as opposed to intra-laboratory variation, which is typically reported. Intra-laboratory CVs are usually calculated by measuring a single sample in 10 or more replicates on several days on the very same platform, resulting in a large number of measurements for a sample (typically a pathologic and a normal control sample are used for CV determination). In our exercise, however, although the number of samples was much higher (95), the number of measurements for each sample was low (three to five, Table 2 ), and every measurement point was performed in a different laboratory. This protocol, naturally, results in a higher CV. Therefore, the CV results cannot be compared with what is reported in the literature, but they still seem useful because they represent 'real life' variability and they can be compared with each other. As has been found by others, CVs were higher in the pathologic range than in the normal range. With the exception of VWF:GPIbR using the HemosIL assay, all new assays showed better reproducibility than the VWF:RCo test in spite of the higher number of measurements for VWF:RCo (five vs. three to four, Table 2 ). The reason for the slightly higher CV for the HemosIL assay is unclear; such a difference has not been found in previous studies. In principle, the use of different calibrators in different laboratories could potentially explain some of the variation. To introduce a uniform calibrator, we distributed the SSC VWF calibrator plasma. However, because of restricted availability of the SSC plasma, only two laboratories were able to perform two assays using the additional calibrator (Fig. 4) . The two calibrators yielded nearly identical results and, therefore, we do not believe that calibrators contributed to the observed CV. In conclusion, all VWF activity assays correlated well with each other and with the VWF:RCo assay. The slight differences in characteristics found in the COMPASS-VWF study will assist the VWF community in interpreting and comparing activity results.
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